PepGen to Participate in Upcoming Investor Conferences
PepGen (Nasdaq: PEPG), a clinical-stage biotechnology company focused on developing oligonucleotide therapies for severe neuromuscular and neurological diseases, has announced its participation in two upcoming investor conferences. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference in Boston on November 11, 2024, at 1:00 p.m. ET, and at the Stifel 2024 Healthcare Conference in New York on November 19, 2024, at 11:30 a.m. ET. Both presentations will be available via webcast on PepGen's website, with replays accessible for 90 days afterward.
PepGen (Nasdaq: PEPG), una società biotecnologica in fase clinica focalizzata sullo sviluppo di terapie a base di oligonucleotidi per gravi malattie neuromuscolari e neurologiche, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda presenterà alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim a Boston l'11 novembre 2024, alle 13:00 ET, e alla Conferenza Sanitaria 2024 di Stifel a New York il 19 novembre 2024, alle 11:30 ET. Entrambe le presentazioni saranno disponibili in streaming sul sito web di PepGen, con le registrazioni accessibili per 90 giorni dopo l'evento.
PepGen (Nasdaq: PEPG), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias de oligonucleotidos para enfermedades neuromusculares y neurológicas severas, ha anunciado su participación en dos próximas conferencias para inversores. La compañía presentará en la Conferencia Inaugural de Innovación Sanitaria de Guggenheim en Boston el 11 de noviembre de 2024, a la 1:00 p.m. ET, y en la Conferencia Sanitaria 2024 de Stifel en Nueva York el 19 de noviembre de 2024, a las 11:30 a.m. ET. Ambas presentaciones estarán disponibles a través de webcast en el sitio web de PepGen, con repeticiones accesibles durante 90 días después del evento.
PepGen (Nasdaq: PEPG), 심각한 신경근 및 신경 질환을 위한 올리고뉴클레오타이드 요법 개발에 집중하는 임상 단계 생명공학 회사는 두 개의 예정된 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 2024년 11월 11일 오후 1시 ET에 보스턴에서 열리는 구겐하임의 첫 번째 헬스케어 혁신 회의와 2024년 11월 19일 오전 11시 30분 ET에 뉴욕에서 열리는 스티펠 2024 헬스케어 회의에서 발표할 예정입니다. 두 발표 모두 PepGen의 웹사이트를 통해 웹캐스트로 제공되며, 행사가 끝난 후 90일 동안 재생이 가능합니다.
PepGen (Nasdaq: PEPG), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies par oligonucleotides pour des maladies neuromusculaires et neurologiques sévères, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société présentera à la Conférence Inaugurale d'Innovation Sanitaire de Guggenheim à Boston le 11 novembre 2024 à 13h00 ET, et à la Conférence Sanitaire 2024 de Stifel à New York le 19 novembre 2024 à 11h30 ET. Les deux présentations seront disponibles en webcast sur le site de PepGen, avec des rediffusions accessibles pendant 90 jours après l'événement.
PepGen (Nasdaq: PEPG), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Oligonukleotidtherapien für schwere neuromuskuläre und neurologische Erkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 11. November 2024 um 13:00 Uhr ET auf der Ersten Gesundheitsinnovationskonferenz von Guggenheim in Boston und am 19. November 2024 um 11:30 Uhr ET auf der Stifel 2024 Gesundheitskonferenz in New York präsentieren. Beide Präsentationen werden über ein Webcast auf der Website von PepGen verfügbar sein, mit Zugriff auf die Aufzeichnungen für 90 Tage nach der Veranstaltung.
- None.
- None.
-
Guggenheim's Inaugural Healthcare Innovation Conference (
Boston, MA )- Monday, November 11, 2024 at 1:00 p.m. ET, Fireside Chat
-
Stifel 2024 Healthcare Conference (
New York, NY )- Tuesday, November 19, 2024 at 11:30 a.m. ET, Fireside Chat
A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the PepGen website at https://investors.pepgen.com/. Replays of the webcasts will be available on the PepGen website for 90 days following the presentation dates.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104983620/en/
Investor Contact
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
FAQ
When is PepGen (PEPG) presenting at the Guggenheim Healthcare Innovation Conference in 2024?
What time is PepGen's (PEPG) presentation at the Stifel 2024 Healthcare Conference?
How long will PepGen's (PEPG) investor conference webcasts be available for replay?
Where can I watch PepGen's (PEPG) investor conference presentations?
